Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAN 2020 | LIBERTY trial: erenumab in episodic migraine patients with prior preventive treatment failures

Uwe Reuter, MD, PhD, MBA, Charité – University Medicine Berlin, Berlin, Germany, discusses the 2-year interim results of the LIBERTY trial (NCT03096834). This study evaluated the efficacy and safety of erenumab in episodic migraine patients who have unsuccessfully failed other preventive migraine treatments. This interview was recorded during an online conference call with The Video Journal of Neurology (VJNeurology).